Application of RSK signal channel inhibitors to restraining chlamydia trachomatis infection

A technology of Chlamydia trachomatis and signaling pathway, which is applied in the field of biomedicine and can solve problems such as no reports of Chlamydia infection-assisted targeted host therapy.

Active Publication Date: 2019-06-07
DERMATOLOGY HOSPITAL SOUTHERN MEDICAL UNIV (GUANGDONG PROVINCIAL DERMATOLOGY HOSPITAL GUANGDONG PROVINCIAL CENT FOR STI & SKIN DISEASES CONTROL & PREVENTION RES CENT FOR LEPROSY CONTROL & PREVENTION CHINA)
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although targeted host therapy strategies have made some progress in the treatment of HIV, tuberculosis and fungal infections, there have been no reports of assisted host-targeted therapy for chlamydial infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RSK signal channel inhibitors to restraining chlamydia trachomatis infection
  • Application of RSK signal channel inhibitors to restraining chlamydia trachomatis infection
  • Application of RSK signal channel inhibitors to restraining chlamydia trachomatis infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1 LJH685 and LJI308 inhibit Chlamydia infection

[0060] The purpose of this example is to clarify the role of RSK signaling pathway inhibitors LJH685 and LJI308 in Chlamydia infection. Hela cells were cultured and inoculated with Chlamydia trachomatis type D. Set up positive and negative controls at the same time. Centrifuge the inoculated 24-well culture plate at 35°C and 1500g for 1h. After centrifugation, suck all the inoculated sample solution, replace each well with DMEM medium containing 1 μg / ml cycloheximide, add 80 μM LJH685 and 20 μM LJI308, 5% CO 2 1. Cultivate for 48 hours under the condition of constant temperature and humidity at 35°C, and then observe the results. Chlamydia inclusion bodies were observed under an inverted microscope by iodine staining and immunofluorescence. Randomly count 20 400-fold visual fields, and calculate the infection rate of chlamydia. 48 hours after infection, collect 80 μM LJH685 and 20 μM LJI308-treated cells wit...

Embodiment 2

[0075] Example 2 LJH685 and LJI308 have similar effects in different cell lines

[0076] The purpose of this example is to clarify the role of LJH685 and LJI308 in different cells. Rat fibroblast McCoy cells and green monkey kidney Vero cells were cultured and inoculated with Chlamydia trachomatis type D. Set up positive and negative controls at the same time. Centrifuge the inoculated 24-well culture plate at 35°C and 1500g for 1h. After centrifugation, suck all the inoculated sample solution, replace each well with DMEM medium containing 1 μg / ml cycloheximide, add 40 μM LJH685 and 20 μM LJI308, 5% CO 21. Cultivate for 48 hours under the condition of constant temperature and humidity at 35°C, and then observe the results. Chlamydia inclusion bodies were observed under an inverted microscope by iodine staining and immunofluorescence. Randomly count 20 400-fold visual fields, and calculate the infection rate of chlamydia. 48 hours after infection, collect 80 μM LJH685 and ...

Embodiment 3

[0092] Example 3 LJH685 and LJI308 have similar effects on different serotypes of Chlamydia infection

[0093] The purpose of this example is to clarify the role of LJH685 and LJI308 in different serotypes of Chlamydia infection. The specific experimental methods and results are as follows:

[0094] 1. Experimental method:

[0095] Hela cells were cultured and inoculated with Chlamydia trachomatis. Iodine staining method and immunofluorescence method were used to observe Chlamydia inclusion bodies under an inverted microscope, calculate the infection rate of Chlamydia, reinoculate Chlamydia trachomatis, and count the number of infectious Chlamydia.

[0096] 2. Experimental results:

[0097] The result is as Figure 15-16 :

[0098] Figure 15 : The role of LJH685 and LJI308 in L1 Chlamydia infection: Hela cells were infected with L1 serotype Chlamydia trachomatis, and found that LJH685 and LJI308 can inhibit the infection of L1 serotype Chlamydia. Immunofluorescence obs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of RSK signal channel inhibitors to restraining chlamydia trachomatis infection. Through research, the inventor finds that RSK signal channel inhibitors LJH685 and LJI308 can restrain chlamydia trachomatis infection and are effective on the chlamydia trachomatis of different cell types and different serotypes, and the RSK signal channel inhibitors are appliedto the chlamydia trachomatis infection for the first time, and hopefully become new medicines for chlamydia trachomatis targeted host treatment. Besides, through research, the inventor also finds that when the RSK signal channel inhibitors LJH685 and LJI308 and azithromycin are in united application, synergistic effects can be achieved, after the chlamydia trachomatis infection, the LJH685 and the LJI308 can promote the anti-infection effect of the azithromycin, and the RSK signal channel inhibitors have important application value on treating the chlamydia trachomatis infection. The RSK signal channel inhibitors have important significance on developing the new medicines for the chlamydia trachomatis infection and seeking new target points for auxiliary host treatment.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to the application of RSK signaling pathway inhibitors in inhibiting Chlamydia trachomatis infection. Background technique [0002] Chlamydia trachomatis (Ct) infection seriously endangers human reproductive health, is one of the most prevalent sexually transmitted diseases in the world, and has become a global public health problem. If Ct infection is not treated in time, it can cause serious complications, such as male epididymitis and prostatitis, female cervicitis, pelvic inflammatory disease, salpingitis, ectopic pregnancy and infertility, etc.; it can also spread through the birth canal, causing neonatal eyes Conjunctivitis and pneumonia. In addition, Ct infection is also a synergistic factor for human papillomavirus-induced cervical cancer and an important synergistic factor for HIV infection. Therefore, Ct infection and widespread transmission have bec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/496A61K31/5377A61K31/7052A61P31/04
Inventor 薛耀华郑和平荣知立
Owner DERMATOLOGY HOSPITAL SOUTHERN MEDICAL UNIV (GUANGDONG PROVINCIAL DERMATOLOGY HOSPITAL GUANGDONG PROVINCIAL CENT FOR STI & SKIN DISEASES CONTROL & PREVENTION RES CENT FOR LEPROSY CONTROL & PREVENTION CHINA)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap